Celltrion’s autoimmune disease treatment “Remsima (ingredient name: infliximab)” has surpassed annual sales of KRW 1 trillion for the second consecutive year, firmly maintaining its position as Korea’s first global blockbuster pharmaceutical product. Industry assessments attribute this performance to its overwhelming market share in key overseas markets such as the United States and Europe, as well as diversification of formulations. This year, the company is aiming for another quantum leap by launching the first liquid formulation among infliximab products.

Celltrion announced on the 10th that Remsima’s global sales in 2025 were tallied at KRW 1,049.5 billion. The company explained that thanks to stable prescription trends worldwide and expansion of the infliximab market in Europe, it achieved annual sales exceeding KRW 1 trillion for the second year in a row following 2024.

In particular, Europe’s expanding infliximab market itself is said to have had a positive impact on Remsima’s growth. The European infliximab market recorded an average annual growth rate of about 9% over the six years from 2019 to 2024. Following the COVID-19 pandemic, demand has increased for subcutaneous (SC) formulations that can be self-administered conveniently regardless of location, rather than in-hospital prescriptions, leading to a sharp expansion in prescriptions for “Remsima SC.” In addition, the acceleration of the dual formulation effect—where patients switch from competing infliximab products to Remsima and then transition to Remsima SC—has expanded prescriptions for both formulations (IV and SC).

Remsima is in fact showing overwhelming prescription performance across Europe. As of the third quarter of last year, Remsima’s market share in the five major European countries (EU5) was 62% in the United Kingdom, 49% in Spain, and 48% in Germany. It is also leading the overall market by achieving notable shares in other European countries, including 75% in Ireland and 64% in Austria. Celltrion’s Remsima is seeking to achieve further growth again this year. Celltrion intends to secure a new growth driver through the newly added liquid formulation. According to the company, compared with the existing lyophilized formulation, the liquid formulation can reduce preparation time by more than 50% and cut related costs such as labor and consumables by around 20%. As no storage equipment is required to maintain a frozen state, it is also known to save related costs for storage space and storage fees. Celltrion stated that hospitals have high expectations for the Remsima liquid formulation, which is friendly to the medical environment and offers administrative and cost-saving benefits. The company plans to start launching the Remsima liquid formulation sequentially across Europe beginning with Northern Europe at the end of this month. Analysts note that diversification of formulations will highlight the product’s competitiveness and further enhance brand recognition.

While Remsima maintains its status as Korea’s first global blockbuster pharmaceutical product, the second blockbuster title is expected to go to Remsima SC, the SC formulation. Remsima SC’s global sales last year are projected to reach around KRW 839.4 billion, up nearly 40% from the previous year (KRW 600.7 billion). On the back of this growth, the company expects its annual sales this year to comfortably surpass KRW 1 trillion. Remsima SC, which was launched in the United States with new drug status as a first-mover product, continues to show steep growth. In the third quarter of last year, it recorded a market share of more than 30% for the first time in the EU5 market, and in the United States it has maintained a monthly average prescription growth rate in the 30% range, continuously setting new records for weekly prescription volume.

A Celltrion official said, “As Remsima, which has surpassed annual sales of KRW 1 trillion for two consecutive years, firmly maintains its position as a global blockbuster therapy, the new liquid formulation to be introduced this year is drawing attention from medical sites even before its launch, raising expectations for its successful market penetration,” adding, “This year, following Remsima, we will do our utmost to ensure that the rapidly growing Remsima SC can emerge as Korea’s second global blockbuster pharmaceutical product.”

Popular News